The short version of prohibited substance fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Perchloric acid forms perchlorate esters, e.g., methyl perchlorate (CH3−O−Cl(=O)3) Sulfuric acid forms sulfate esters, e.g., dimethyl sulfate ((CH3−O−)2S(=O)2) and methyl bisulfate (CH3−O−S(=O)2−OH) Nitric acid forms nitrate esters, e.g. methyl nitrate (CH3−O−NO2) and nitroglycerin (CH(−O−NO2)(−CH2−O−NO2)2) Phosphoric acid forms phosphate esters, e.g. triphenyl phosphate (O=P(−O−C6H5)3) and methyl dihydrogen phosphate (O=P(−O−CH3)(−OH)2) Pyrophosphoric (diphosphoric) acid forms pyrophosphate esters, e.g. tetraethyl pyrophosphate, ADP, dADP, ADPR, cADPR, CDP, dCDP, GDP, dGDP, UDP, dTDP, MEcPP, HMBPP, DMAPP, IPP, GPP, FPP, GGPP, ThDP, FAD, NAD, NADP. Triphosphoric acid forms triphosphate esters, e.g. ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, dTTP, ITP, XTP, ThTP, AThTP. Tetraphosphoric acid forms tetraphosphate esters, e.g. hexaethyl tetraphosphate, adenosine tetraphosphate (ATPP, Ap4), Ap4A. Carbonic acid forms carbonate esters, e.g. dimethyl carbonate ((CH3−O−)2C=O) and 5-membered cyclic ethylene carbonate ((−CH2−O−)2C=O) (if one classifies carbonic acid as an inorganic compound) Trithiocarbonic acid forms trithiocarbonate esters, e.g. dimethyl trithiocarbonate ((CH3−S−)2C=S) (if one classifies trithiocarbonic acid as an inorganic compound) Chloroformic acid forms chloroformate esters, e.g. methyl chloroformate (Cl−C(=O)−O−CH3) (if one classifies chloroformic acid as an inorganic compound) Boric acid forms borate esters, e.g.
==== Extracellular matrix ==== The extracellular matrix (ECM) surrounds the cardiomyocyte and fibroblasts. The ECM is composed of proteins including collagen and elastin along with polysaccharides (sugar chains) known as glycosaminoglycans. Together, these substances give support and strength to the muscle cells, create elasticity in cardiac muscle, and keep the muscle cells hydrated by binding water molecules. The matrix in immediate contact with the muscle cells is referred to as the basement membrane, mainly composed of type IV collagen and laminin. Cardiomyocytes are linked to the basement membrane via specialised glycoproteins called integrins.
The skin of the hands and fingers and the feet and toes is known by forensic scientists as friction ridge skin. It is known by anatomists as thick skin, volar skin or hairless skin. It has raised ridges, a thicker and more complex epidermis, increased sensory abilities, and the absence of hair and sebaceous glands. The ridges increase friction for improved grasping. In mucous membranes, the equivalent structures to dermal papillae are generally termed "connective tissue papillae", which interdigitate with the rete pegs of the superficial epithelium. Dermal papillae are less pronounced in thin skin areas.
== Production and function == Hydroxyproline is produced by hydroxylation of the amino acid proline by the enzyme prolyl 4-hydroxylase following protein synthesis (as a post-translational modification). The enzyme-catalyzed reaction takes place in the lumen of the endoplasmic reticulum. Although it is not directly incorporated into proteins, hydroxyproline comprises roughly 4% of all amino acids found in animal tissue, an amount greater than seven other amino acids that are translationally incorporated.
Sources: en.wikipedia.org
For the [Special Rapporteur on the right to health], the dominance of the biomedical model to explain emotional distress has resulted in the overuse of medicalisation and institutionalisation, while ignoring the social, political or existential contexts that contribute to manifestations of mental distress.
== Recalls == In 2018–2019, Teva Pharmaceuticals USA recalled antihypertensive tablets containing valsartan and losartan due to the detection beyond acceptable limit of N-nitrosodiethylamine (NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), respectively, which are probable human carcinogens.
Blind: Only one open end; may also be called sinus tracts. Complete: Both internal and external openings. Incomplete: An external skin opening that does not connect to any internal organ. Although most fistulas are in forms of a tube, some can also have multiple branches.
Sources: en.wikipedia.org
The Achilles tendon is the muscle tendon of the triceps surae, a "three-headed" group of muscles—the soleus and the two heads of the gastrocnemius. The main function of the triceps surae is plantar flexion, i.e. to stretch the foot downward. It is accompanied by a "fourth head", the slight plantaris muscle, the long slender tendon of which is also attached to the heel bone but not visible.
=== Nausea === Diphenhydramine also has antiemetic properties, which makes it useful in treating the nausea that occurs in vertigo and motion sickness. However, when taken above the recommended doses, it can cause nausea (especially above 200 mg). Diphenhydramine is the active ingredient in Dramamine, aka Gravol.
=== Controlled-release formulations === Controlled or modified-release formulations are designed to deliver medications at a steady rate over time, helping maintain consistent drug levels in the bloodstream. This steady release reduced how often patients need to take their medication and minimizes the ups and downs in drug concentration that can cause side effects or lower effectiveness. These systems often take the form of matrix tablets, osmotic pumps, and reservoir-type devices, all of which use physical or chemical barriers to regulate how the drug is released. This approach is especially useful for chronic conditions such as high blood pressure, diabetes, or chronic pain, where maintaining stable therapeutic levels is key to keeping symptoms under control. The concept of controlled-release medication dates back to the 1950s, when Dexedrine became the first such formulation on the market. This era saw the introduction of transdermal patches, which deliver drugs slowly through the skin. As technology progressed, new formulations were developed to match the specific properties of different drugs. Examples include long-acting depot injections for medication like antipsychotics and hormone therapies, which remain effective for weeks or even months after a single dose. Since the late 1990s, research has increasingly turned to nanotechnology as a way to improve controlled-released drug delivery.
=== Cystic fibrosis === Cystic fibrosis (CF) was first added to newborn screening programs in New Zealand and regions of Australia in 1981, by measuring immunoreactive trypsinogen (IRT) in dried blood spots. After the CFTR gene was identified, Australia introduced a two tier testing program to reduce the number of false positives. Samples with an elevated IRT value were then analyzed with molecular methods to identify the presence of disease causing mutations before being reported back to parents and health care providers. CF is included in the core panel of conditions recommended for inclusion in all 50 states, Texas was the last state to implement their screening program for CF in 2010. Alberta was the first Canadian province to implement CF screening in 2007. Quebec, New Brunswick, Nova Scotia, Newfoundland and Prince Edward Island do not include CF in their screening programs. The United Kingdom as well as many European Union countries screen for CF as well. Switzerland is one of the latest countries to add CF to their newborn screening menu, doing so in January 2011.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.